Journal & Article

Biochemistry & Molecular Biology

I/F
# Journal I/F

NATURE MEDICINE

Nature Portfolio Commissions: data-driven solutions to global problems. Sustaining kidney failure care under universal health coverage. The path to safe, equitable and sustainable dialysis provision for people with chronic kidney disease. Nature Medicine Commission on dialysis policy in low- and middle-income countries. Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial. Contaminating plasmid sequences and disrupted vector genomes in the liver following adeno-associated virus gene therapy. External trigeminal nerve stimulation in youth with ADHD: a randomized, sham-controlled, phase 2b trial. Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial. Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990-2023: a Global Burden of Disease Study. Single-cell atlas of the developing Down syndrome brain cortex. An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial. Lessons from Rwanda's response to the Marburg virus outbreak. The new vision from the National Institute of Allergy and Infectious Diseases (NIAID). Interpretable inflammation landscape of circulating immune cells. Holistic evaluation of large language models for medical tasks with MedHELM. Placebo effect influences vaccine responses. Upregulation of reward mesolimbic activity and immune response to vaccination: a randomized controlled trial. An LLM chatbot to facilitate primary-to-specialist care transitions: a randomized controlled trial. Principles to guide clinical AI readiness and move from benchmarks to real-world evaluation. Reorienting Ebola care toward human-centered sustainable practice. Immune cells in circulation serve as living biomarkers for inflammatory diseases. Clinical genetic variation across Hispanic populations in the Mexican Biobank. The Translational Research and Innovation Laboratory (TRAIL) model for accelerating discovery through a shared institutional resource. Clinically relevant variants from the Mexican biobank show striking diversity across Hispanic people. Humoral IgG1 responses to tumor antigens underpin clinical outcomes in immune checkpoint blockade. Professional medical associations as catalytic pathways for advancing women in academic medicine and promoting leadership. Student-led efforts promoting inclusivity and belonging in US medical schools. Publisher Correction: Interpretable inflammation landscape of circulating immune cells. Publisher Correction: argeting of HIF2-driven cachexia in kidney cancer. Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial. Fecal microbiota transplantation plus immunotherapy in metastatic renal cell carcinoma: the phase 1 PERFORM trial. Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial. Author Correction: Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial. Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial. New analysis shows no link between autism and paracetamol. Base editing enables off-the-shelf CAR T cells for leukemia. Multi-omic definition of metabolic obesity through adipose tissue–microbiome interactions The expanding landscape of GLP-1 medicines Lessons in public trust Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial Shared and specific blood biomarkers for multimorbidity Mechanistic insights make cancer cachexia a targetable syndrome A One Health trial design to accelerate Lassa fever vaccines Generative AI-based low-dose digital subtraction angiography for intra-operative radiation dose reduction: a randomized controlled trial When science meets violence Early successes in colon immunotherapy Reply to Ludwig, D. S. et al.; Robinson, E. & Forde, C. G.; Wang, Z. & Peng, C. Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial Building a code of conduct for AI-driven clinical consultations Concerns over conclusions in an ultra-processed food trial